Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study, participants with complex fistulizing conditions will be treated with surgical interventions according to their clinic's standard practice.
The aim of the study is to generate real-world evidence on standard of care for surgical interventions and related outcomes when treating complex fistulizing conditions.
The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study.
This is a non-interventional, prospective study of participants with complex fistulizing conditions (CPF-CD, CD develops CD-RVF and CCF) who are currently undergoing surgical intervention in the real world clinical setting.
The study will enroll approximately 750 participants. The data will be collected prospectively at the study sites and will be recorded into electronic data capture forms (EDCs). Participants will be enrolled to the following observational cohorts:
This multi-center study will be conducted in the United States, Canada, Europe, and Israel. Participants undergoing surgical interventions to treat fistulas will be enrolled from surgical and gastrointestinal (GI) specialty sites. The overall duration of the study will be 24 months. Data will be collected at baseline with follow-up information collected approximately every 3 to 6 months.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants With CPF-CD | Participants diagnosed with CPF-CD will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery. | ||
| Participants With CD-RVF | Participants diagnosed with CD-RVF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery. | ||
| Participants With CCF | Participants diagnosed with CCF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants who Achieve Clinical Remission of Fistula | Clinical remission for Complex perianal fistula in Crohn's Disease (CPF-CD) and Complex Cryptoglandular Fistula (CCF) is defined as closure of all index treated external fistula openings that were draining at baseline as assessed clinically despite gentle finger compression. Clinical remission for Rectovaginal fistula with Crohn's Disease (CD-RVF) is defined as epithelization of the index external fistula opening (vaginal opening) compared to baseline. | Baseline up to 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Post-surgical Complications | Post-surgical complications for CPF-CD and CCF is defined as post-index surgery perianal pain, bleeding, infection, urinary retention, delayed or poor wound healing, anal stenosis, and fecal incontinence related to index surgery. Post-surgical complications for CD-RVF is defined as post-index surgery vaginal bleeding, infection, urinary retention, urinary tract infections (UTIs), discharge, delayed or poor wound healing, anal stenosis, fecal incontinence, and pain with intercourse or others related to index surgery. |
Not provided
Inclusion Criteria:
Participants with CPF-CD
CPF-CD that meets one or more of the following criteria:
Physician has made the decision to treat with a specific surgical intervention. Procedures may include:
Participants with CD-RVF: Rectovaginal fistula per physician diagnosis
1. Physician has made the decision to treat with a specific surgical intervention. Procedures may include:
Participants with CCF:
Complex cryptoglandular fistula that meets one or more of the following criteria:
Physician has made the decision to treat with a specific surgical intervention. Procedures may include:
Exclusion Criteria:
Participants who meet any below mentioned criterion among CPF-CD, CD-RVF, and CCF diagnosis will be excluded from the study.
Not provided
Not provided
Not provided
Participants undergoing surgical interventions to treat fistulas (CPF-CD, CD-RVF and CCF) from surgical and GI specialty sites.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Study Director | Takeda | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | United States | ||
| Baptist MD Anderson Cancer Center |
Not provided
| Label | URL |
|---|---|
| To obtain more information about this study, click this link. | View source |
| Click here to ask Takeda's chatbot for comprehensive and easy-to-understand information about clinical trials - even across products and indications - in your local language. | View source |
Not provided
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Not provided
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Not provided
Not provided
Not provided
Not provided
| Baseline, 3, 6, 12 and 24 months post-index surgery |
| Percentage of Participants who Achieve Combined Remission | Combined remission for CPF-CD and CCF is defined as closure of all index external fistula openings treated with surgery that were draining at baseline as assessed clinically despite gentle finger compression, and absence of fluid collections greater than (>) 2 centimeter (cm) in at least 2 dimensions, as confirmed by pelvic magnetic resonance imaging (MRI) or other imaging procedure. Combined remission for CD-RVF is defined as 100 percent (%) cessation of drainage on both clinical exam with deep palpation (deeper bimanual exam/palpation with speculum and/or anoscope) and epithelization of the index external fistula opening (vaginal opening) compared to baseline; and absence of fluid collection as assessed by MRI or other imaging procedure. | Baseline, 3, 6, 12 and 24 months post-index surgery |
| Percentage of Participants who Achieve Cessation of Drainage in Treated Fistula | Cessation of drainage for CPF-CD and CCF is defined as 100% cessation of drainage from index treated fistula, as assessed clinically. Cessation of drainage for CD-RVF is defined as 100% cessation of drainage on clinical exam with deep palpation (deeper bimanual exam/palpation with speculum and/or anoscope) from the index treated fistula. | Baseline, 3, 6, 12 and 24 months post-index surgery |
| Percentage of Participants With Relapse of Fistula in Clinical Remission | Relapse for CPF-CD and CCF is defined as reopening of any surgically treated index fistulae as clinically assessed; or the development of a perianal fluid collection >2 cm in at least 2 dimensions of the perianal fistula(s) treated, confirmed by MRI assessment or other imaging procedure; or drainage. Relapse for CD-RVF is defined as reopening of any surgically treated index fistulae as clinically assessed; or appearance of fluid collection as assessed by MRI or other imaging procedure; or drainage. | Baseline, 3, 6, 12 and 24 months post-index surgery |
| Percentage of Participants With New Perianal Abscess | Baseline, 3, 6, 12 and 24 months post-index surgery |
| Jacksonville |
| Florida |
| 32207 |
| United States |
| University of South Florida - PARENT | Tampa | Florida | 33612 | United States |
| University of Kansas Medical Center Research Institute, Inc. | Kansas City | Kansas | 66160 | United States |
| GI Alliance - Baton Rouge | Baton Rouge | Louisiana | 70809 | United States |
| Lenox Hill Hospital PRIME | New York | New York | 10075 | United States |
| UNC Hospitals | Chapel Hill | North Carolina | 27599 | United States |
| Premier Health | Dayton | Ohio | 45409 | United States |
| Penn Medicine PA | Philadelphia | Pennsylvania | 19104 | United States |
| Temple University Hospital | Philadelphia | Pennsylvania | 19140 | United States |
| Vanderbilt University Medical Center- GI Endoscopy Lab | Nashville | Tennessee | 37212 | United States |
| Baylor Research Institute | Dallas | Texas | 75204 | United States |
| Colon & Rectal Clinic | Houston | Texas | 77030 | United States |
| AKH - Medizinische Universitat Wien | Vienna | 1090 | Austria |
| UZ Antwerpen | Antwerp | 2650 | Belgium |
| Cliniques Universitaires Saint-Luc | Brussels | 1200 | Belgium |
| Jessa Ziekenhuis Hospital | Hasselt | 3500 | Belgium |
| Clinique CHC MontLegia | Liège | 4000 | Belgium |
| AZ Delta | Roeselare | 8800 | Belgium |
| St. Pauls Hospital | Vancouver | British Columbia | V6Z 1Y6 | Canada |
| Fakultni nemocnice Brno | Brno | 625 00 | Czechia |
| Fakultni nemocnice u sv. Anny v Brne | Brno | 656 91 | Czechia |
| NH Hospital a.s.Nemocnice Horovice | Hořovice | 268 31 | Czechia |
| Fakultni nemocnice Olomouc | Olomouc | 779 00 | Czechia |
| Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud | Pierre-Bénite | Bouches-du-Rhone | 69310 | France |
| Fondation Maison Sante Bagatelle | Talence | Gironde | 33400 | France |
| CHU de Rennes - Hopital Pontchaillou | Rennes | Ille Et Vilaine | 35000 | France |
| CHRU Hopital Claude Huriez | Lille | Nord | 59037 | France |
| CHU de Rouen - Hopital Charles Nicolle | Rouen | Seine Maritime | 76031 | France |
| Groupe Hospitalier Diaconesses - Hopital De La Croix Saint Simon | Paris | 75012 | France |
| Hopital Saint Joseph - Paris | Paris | 75014 | France |
| Shamir Medical Center (Assaf Harofeh) | Be’er Ya‘aqov | 7033001 | Israel |
| Rambam Health Care Center | Haifa | 3109601 | Israel |
| Wolfson Medical Center | Holon | 58100 | Israel |
| Tel Aviv Sourasky Medical Center | Tel Aviv | 64239 | Israel |
| Istituto Clinico Humanitas | Rozzano | Milano | 20089 | Italy |
| Amsterdam UMC, Locatie AMC | Amsterdam | 1105 AZ | Netherlands |
| UMC Utrecht | Utrecht | 3508 GA | Netherlands |
| Broomfield Hospital | Chelmsford | Essex | CM1 7ET | United Kingdom |
| Nottingham University Hospital | Nottingham | Nottinghamshire | NG7 2UH | United Kingdom |
| Royal Victoria Infirmary. | Newcastle upon Tyne | Tyne & Wear | NE1 4LP | United Kingdom |
| ID | Term |
|---|---|
| D003424 | Crohn Disease |
| D005402 | Fistula |
| D012006 | Rectovaginal Fistula |
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012003 | Rectal Fistula |
| D007412 | Intestinal Fistula |
| D016154 | Digestive System Fistula |
| D012002 | Rectal Diseases |
| D014624 | Vaginal Fistula |
| D014623 | Vaginal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
Not provided
Not provided